“Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s660, https://doi.org/10.25251/1g590e41.